Prime Medicine PRME
$3.55 −$0.29 (-7.55%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $3.56 +0.28%
Open$3.70
Prev close$3.84
Day range$3.49 – $3.94
Volume6.13M
Market cap$791.62M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$4.21M+243.9% YoY
Operating profit-$39.93M+26.0% YoY
Net profit-$39.04M+22.8% YoY
Diluted EPS-$0.22+31.3% YoY
Free cash flow-$36.98M-4.8% YoY
Operating cash flow-$36.68M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-2,584.2%
Net margin-2,497.6%
Return on equity-207.2%
Return on assets-58.9%
Return on invested capital-90.2%
Current ratio1.79
Liabilities / assets96.1%
Cash & investments$61.16M
Total debt$101.01M
Net cash (debt)-$39.85M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $4.21M | $1.15M | $856,000.00 | $4.63M | $838,000.00 |
| Total Operating Revenue | $4.21M | $1.15M | $856,000.00 | $4.63M | $838,000.00 |
| Operating Expense | $44.14M | $44.44M | $51.51M | $212.98M | $49.45M |
| Selling and Admin Expenses | $10.02M | $11.04M | $17.41M | $52.35M | $14.74M |
| -General & Admin Expense | $10.02M | $11.04M | $17.41M | $52.35M | $14.74M |
| Research & Development | $34.12M | $33.40M | $34.11M | $160.64M | $34.71M |
| Operating Profit | -$39.93M | -$43.29M | -$50.65M | -$208.35M | -$48.61M |
| Net Non-Operating Interest Income (Expense) | $555,000.00 | $788,000.00 | $1.02M | $4.15M | $1.08M |
| Non-Operating Interest Income | $555,000.00 | $788,000.00 | $1.02M | $4.15M | $1.08M |
| Other Income (Expense) | $328,000.00 | $388,000.00 | $511,000.00 | $3.06M | $1.45M |
| Securities Amortization | -$274,000.00 | -$333,000.00 | -$460,000.00 | -$2.48M | -$858,000.00 |
| Other Non-Operating Income (Expenses) | $54,000.00 | $55,000.00 | $51,000.00 | $148,000.00 | $49,000.00 |
| Pretax Profit | -$39.04M | -$42.11M | -$49.12M | -$201.14M | -$46.08M |
| Net Profit | -$39.04M | -$42.11M | -$49.12M | -$201.14M | -$46.08M |
| Profit from Continuing Operations | -$39.04M | -$42.11M | -$49.12M | -$201.14M | -$46.08M |
| Net Income to Parent Company | -$39.04M | -$42.11M | -$49.12M | -$201.14M | -$46.08M |
| Net Income to Common Stockholders | -$39.04M | -$42.11M | -$49.12M | -$201.14M | -$46.08M |
| Basic EPS | -$0.22 | -$0.24 | -$0.28 | -$1.35 | -$0.24 |
| Diluted EPS | -$0.22 | -$0.24 | -$0.28 | -$1.35 | -$0.24 |
| Gain on Sale of Security | – | – | – | $432,000.00 | $539,000.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $213.86M | $249.04M | $294.73M | $342.73M | $342.73M |
| Total Current Assets | $63.69M | $96.80M | $137.89M | $181.29M | $181.29M |
| Cash and Cash Equivalents & Short-Term Investments | $61.16M | $47.45M | $135.50M | $177.68M | $177.68M |
| -Cash and Cash Equivalents | $54.89M | $47.45M | $64.11M | $63.03M | $63.03M |
| -Short Term Investments | $6.27M | – | $71.39M | $114.65M | $114.65M |
| Other Current Assets | $2.53M | $95.45M | $421,000.00 | $674,000.00 | $674,000.00 |
| Total Non-Current Assets | $150.16M | $152.24M | $156.84M | $161.44M | $161.44M |
| Net PPE | $133.20M | – | $142.15M | $146.75M | $146.75M |
| -Gross PPE | $159.03M | – | $164.44M | $167.18M | $167.18M |
| -Accumulated Depreciation | -$25.83M | – | -$22.29M | -$20.43M | -$20.43M |
| Other Non-Current Assets | $16.97M | $152.24M | $14.69M | $14.69M | $14.69M |
| Total Liabilities | $205.42M | $209.23M | $218.03M | $221.87M | $221.87M |
| Total Current Liabilities | $35.64M | $31.69M | $36.29M | $37.45M | $37.45M |
| Payables | $6.40M | – | $12.33M | $8.89M | $8.89M |
| -Accounts Payable | $6.40M | $5.81M | $12.33M | $8.89M | $8.89M |
| Current Accrued Expenses | $4.49M | $4.65M | $3.76M | $3.56M | $3.56M |
| Short-Term Debt and Capital Lease Obligation | $9.42M | – | $8.55M | $8.14M | $8.14M |
| -Current Capital Lease Obligation | $9.42M | $8.97M | $8.55M | $8.14M | $8.14M |
| Current Deferred Liabilities | $8.98M | – | $7.32M | $7.82M | $7.82M |
| Other Current Liabilities | $1.03M | $31.69M | $2.15M | $1.70M | $1.70M |
| Total Non-Current Liabilities | $169.78M | $177.54M | $181.74M | $184.42M | $184.42M |
| Long Term Debt and Capital Lease Obligation | $101.01M | $103.51M | $105.97M | $108.29M | $108.29M |
| -Long Term Capital Lease Obligation | $101.01M | $103.51M | $105.97M | $108.29M | $108.29M |
| Non-Current Deferred Liabilities | $68.78M | – | $75.78M | $76.13M | $76.13M |
| Total Equity | $8.44M | $39.81M | $76.70M | $120.87M | $120.87M |
| Stockholders' Equity | $8.44M | $2.00B | $76.70M | $120.87M | $120.87M |
| Capital Stock | $2,000.00 | – | $2,000.00 | $2,000.00 | $2,000.00 |
| -Common Stock | $2,000.00 | – | $2,000.00 | $2,000.00 | $2,000.00 |
| Additional Paid-In Capital | $1.03B | $1.02B | $1.01B | $1.01B | $1.01B |
| Retained Earnings | -$1.02B | $979.59M | -$937.48M | -$888.35M | -$888.35M |
| Gains/Losses Not Affecting Retained Earnings | -$3,000.00 | – | -$1,000.00 | $82,000.00 | $82,000.00 |
| Prepaid Assets | – | $1.36M | $1.97M | $2.94M | $2.94M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$36.68M | -$41.05M | -$42.71M | -$162.56M | -$37.26M |
| Net cash flow from continuing operations | -$36.68M | -$41.05M | -$42.71M | -$162.56M | -$37.26M |
| Net Income from Continuing Operations | -$39.04M | -$42.11M | -$49.12M | -$201.14M | -$46.08M |
| Depreciation & Depletion & Amortization | $1.76M | $1.79M | $1.86M | $7.32M | $1.88M |
| Other Non-Cash Items | $2.89M | $2.87M | $2.84M | $9.70M | $2.60M |
| Change in Working Capital | -$6.89M | -$8.14M | -$2.50M | -$5.34M | $1.16M |
| -Change in Prepaid Assets | -$3.08M | $659,000.00 | $1.22M | $4.55M | $2.60M |
| -Change in Payables and Accrued Expense | $2.46M | -$5.64M | -$950,000.00 | -$164,000.00 | $1.02M |
| -Change in Other Current Liabilities | -$4.02M | -$69,000.00 | -$1.92M | -$5.36M | -$1.71M |
| -Change In Other Working Capital | -$2.25M | -$3.09M | -$856,000.00 | -$4.36M | -$751,000.00 |
| Net cash flow from investing | $41.25M | $24.03M | $43.39M | -$108.76M | $28.33M |
| Net Cash Flow from Continuing Investing Activities | $41.25M | $24.03M | $43.39M | -$108.76M | $28.33M |
| Net PPE Purchase and Sale | -$298,000.00 | -$46,000.00 | -$214,000.00 | -$4.53M | -$290,000.00 |
| Net Investment Purchase and Sale | $41.55M | $24.08M | $43.61M | -$104.23M | $28.62M |
| Financing Cash Flow | $2.87M | $361,000.00 | $393,000.00 | $151.51M | $562,000.00 |
| Net Cash Flow from Continuing Financing Activities | $2.87M | $361,000.00 | $393,000.00 | $151.51M | $562,000.00 |
| Proceeds from Stock Option Exercised | $54,000.00 | $361,000.00 | $393,000.00 | $1.12M | $552,000.00 |
| Ending Cash Balance | $68.58M | $61.14M | $77.80M | $76.72M | $76.72M |
| Net Change in Cash | $7.44M | -$16.66M | $1.07M | -$119.82M | -$8.36M |
| Beginning Cash Balance | $61.14M | $77.80M | $76.72M | $196.54M | $85.09M |
| Free Cash Flow | -$36.98M | -$41.09M | -$42.92M | -$167.10M | -$37.55M |
| -Change in Receivables | – | $0.00 | $0.00 | – | – |
| Net Common Stock Issuance | – | – | – | $138.39M | $10,000.00 |
| Net Other Financing Charges | – | – | – | $12.00M | $0.00 |
No comments yet — be the first to weigh in on PRME.
Sign in to join the discussion.